Drug Trial Radar · NCT06505395
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Last checked: Nov 20, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 30, 2024
Primary completion
Aug 1, 2027
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
Conditions
- Gastrointestinal Neuroendocrine Pancreatic Tumor
Interventions
SYHX2008 injectionDrug
The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
Sandostatin LAR@Drug
The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)Time frame: Up to 1 years following the last patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hosptial
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.